1. Comparative study of multilayered nanostructures for enhanced solar optical absorption. Issue 13 (2016) Authors: Dahal, Pabitra; Chou, Jeffrey; Wang, Yu; Kim, Sang Gook; Viegas, Jaime Journal: MRS advances Issue: Volume 1:Issue 13(2016) Page Start: 839 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). (4th November 2015) Authors: Long, Georgina V; Dummer, Reinhard; Ribas, Antoni; Puzanov, Igor; Michielin, Olivier; VanderWalde, Ari; Andtbacka, Robert HI; Cebon, Jonathan; Fernandez, Eugenio; Malvehy, Josep; Olszanski, Anthony J; Gajewski, Thomas F; Kirkwood, John M; Kuznetsova, Olga; Chen, Lisa; Kaufman, David R; Chou, Jeff... Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors. (4th November 2015) Authors: Hecht, J Randolph; Raman, Steven; Sze, Daniel Y; Lockhart, A Craig; Moss, Rebecca A; Liu, Kate; Chou, Jeffrey; Reid, Tony Journal: Journal for immunotherapy of cancer Issue: Volume 3(2015)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort. (15th April 2020) Authors: Chiappori, Alberto; Thompson, John; Eskens, Fredericus; Spano, Jean-Philippe; Doi, Toshihiko; Hamid, Omid; Diab, Adi; Rizvi, Naiyer; Hu-Lieskovan, Siwen; Ros, Willeke; Thomas, Jacob; Forgie, Alison; Yang, Wenjing; Liao, Ken; Li, Ray; Kazazi, Farhad; Chou, Jeffrey; khoueiry, Anthony El Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors. Issue 2 (December 2015) Authors: Hecht, J; Raman, Steven; Sze, Daniel; Lockhart, A; Moss, Rebecca; Liu, Kate; Chou, Jeffrey; Reid, Tony Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). Issue 2 (December 2015) Authors: Long, Georgina; Dummer, Reinhard; Ribas, Antoni; Puzanov, Igor; Michielin, Olivier; VanderWalde, Ari; Andtbacka, Robert; Cebon, Jonathan; Fernandez, Eugenio; Malvehy, Josep; Olszanski, Anthony; Gajewski, Thomas; Kirkwood, John; Kuznetsova, Olga; Chen, Lisa; Kaufman, David; Chou, Jeffrey; Hodi, F Journal: Journal for immunotherapy of cancer Issue: Volume 3:Issue 2(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. Issue 2 (1st February 2021) Authors: Arend, Rebecca C.; Jackson-Fisher, Amy; Jacobs, Ira A.; Chou, Jeffrey; Monk, Bradley J. Journal: Cancer biology & therapy Issue: Volume 22:Issue 2(2021) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Issue 10 (27th October 2022) Authors: Hamid, Omid; Chiappori, Alberto A; Thompson, John A; Doi, Toshihiko; Hu-Lieskovan, Siwen; Eskens, Ferry A L M; Ros, Willeke; Diab, Adi; Spano, Jean-Philippe; Rizvi, Naiyer A; Wasser, Jeffrey S; Angevin, Eric; Ott, Patrick A; Forgie, Alison; Yang, Wenjing; Guo, Cen; Chou, Jeffrey; El-Khoueiry, Ant... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 10(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. Issue 1 (15th April 2019) Authors: Davda, Jasmine; Declerck, Paul; Hu-Lieskovan, Siwen; Hickling, Timothy P.; Jacobs, Ira A.; Chou, Jeffrey; Salek-Ardakani, Shahram; Kraynov, Eugenia Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Melanoma and immunotherapy bridge 2015. Issue 1 (July 2016) Authors: Nanda, Vashisht; Peng, Weiyi; Hwu, Patrick; Davies, Michael; Ciliberto, Gennaro; Fattore, Luigi; Malpicci, Debora; Aurisicchio, Luigi; Ascierto, Paolo; Croce, Carlo; Mancini, Rita; Spranger, Stefani; Gajewski, Thomas; Wang, Yangyang; Ferrone, Soldano; Vanpouille-Box, Claire; Wennerberg, Erik; Pil... Journal: Journal of translational medicine Issue: Volume 14:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗